If the trial is successful, the firm's complete estrogen receptor antagonist would complement its other biomarker-driven breast cancer assets.

If the trial is successful, the firm's complete estrogen receptor antagonist would complement its other biomarker-driven breast cancer assets.

--Best two-day stretch since the two days ending Nov. 11, 2020, when it rose 7.35% --Down 15.77% from its all-time closing high of $87.62 on Aug. 30, 2024 --Up 16.18% from 52 weeks ago (Feb. 8, 2024), ...